Latest Biosimilar Stories
Introduces Chairman Gewanter, shows support for BQ proposal GENEVA, Oct.
A Substantial Need Remains for Emerging SLE Biologics That Can Prevent Acute Flares and That Treat Severe Manifestations, According to Findings from Decision Resources Group BURLINGTON, Mass.,
CRANBURY, N.J., Oct.
Physicians Indicate that Switching of Currently Treated Patients to Biosimilar Infliximab Is Likely to be Limited, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
- BIO Investor Forum to be held October 7-8 in San Francisco - SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Pfenex Inc.
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced a full agenda
- Having a loud voice; vociferous; clamorous.
- Of grand or imposing sound.